X
[{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TCR\u00b2 Therapeutics Announces Veteran Finance Executive Stephen Webster Joins its Board of Directors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TCR\u00b2 Therapeutics to Announce Interim Data from Phase 1\/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"ElevateBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TCR\u00b2 Therapeutics Announces Partnership with Elevatebio to Expand TC-210 Manufacturing Capacity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TCR\u00b2 Therapeutics Announces Positive Interim Results from Ongoing Phase 1\/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TCR\u00b2 Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo\u00ae and Yervoy\u00ae in Mesothelin-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Arbor Biotechnologies, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TCR\u00b2 Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Adaptimmune Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adaptimmune and TCR\u00b2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by TCR2 Therapeutics
Filters
Companies By Therapeutic Area
Details:
The combined company will utilize engineered T-cell therapies targeting MAGE-A4 and mesothelin. These targets are expressed on a broad range of solid tumors and are supported by compelling early- and late-stage clinical data.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Cell and Gene therapy
Recipient:
Adaptimmune Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Merger
March 06, 2023
Details:
Gavo-cel (TC-210) demonstrated a disease control rate (DCR) of 77%, which is defined in the Phase 1 portion of the trial as a response or sustained stable disease for at least three months post infusion.
Lead Product(s):
Gavocabtagene Autoleucel,Nivolumab ,Ipilimumab
Therapeutic Area: Oncology
Product Name: TC-210
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Bristol Myers Squibb
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 28, 2022
Details:
The collaboration leverages Arbor’s proprietary CRISPR gene-editing technology and TCR 2’s’ TRuC platform, which has demonstrated clinical activity in multiple treatment-refractory mesothelin-expressing solid tumor indications with its lead autologous program Gavo-cel.
Lead Product(s):
Gavocabtagene autoleucel,Fludarabine Phosphate ,Cyclophosphamide
Therapeutic Area: Oncology
Product Name: Gavo-cel
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Recipient:
Arbor Biotechnologies, Inc
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
January 04, 2022
Details:
Under clinical trial collaboration, Bristol Myers Squibb to evaluate gavo-cel in combination with Opdivo® (nivolumab) and Yervoy® (ipilimumab) in its planned Phase 2 clinical trial in treatment refractory mesothelin-expressing solid tumors.
Lead Product(s):
Gavocabtagene Autoleucel,Nivolumab
Therapeutic Area: Oncology
Product Name: Gavo-cel
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Recipient:
Bristol Myers Squibb
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
October 25, 2021
Details:
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin for mesothelin-expressing solid tumors.
Lead Product(s):
Gavocabtagene Autoleucel,Fludarabine Phosphate ,Cyclophosphamide
Therapeutic Area: Oncology
Product Name: TC-210
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 17, 2021
Details:
The strategic partnership will focus on the production of TC-210, TCR2’s TRuC-T cell targeting advanced mesothelin-expressing cancer, to support the anticipated Phase II clinical trial.
Lead Product(s):
TC-210 ,Fludarabine Phosphate ,Cyclophosphamide
Therapeutic Area: Oncology
Product Name: TC-210
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Recipient:
ElevateBio
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
November 10, 2020
Details:
Company plans to discuss initial data from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in a premarket press release and webcast to be held on Monday, July 27th, 2020.
Lead Product(s):
TC-210 ,Fludarabine Phosphate ,Cyclophosphamide
Therapeutic Area: Oncology
Product Name: TC-210
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 24, 2020
Details:
Stephen Webster will assist TCR² Therapeutics in advancing their third mono TRuC-T cell therapy towards the clinic.
Lead Product(s):
TC-210 ,Fludarabine Phosphate ,Cyclophosphamide
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 04, 2020